Skip to Main Content
Contribute Try STAT+ Today

A congressional watchdog agency has concluded the Food and Drug Administration properly conducted a review of the controversial Mifeprex abortion pill before relaxing usage guidelines two years ago, a move that prompted complaints by some lawmakers and anti-abortion activists that the shift was politically motivated.

The finding comes amid ongoing tumult over Mifeprex, which was once known as RU-486 and remains a focal point of a long-running cultural clash in the U.S. over access to medically induced abortion. In the final months of the Obama administration, however, the FDA eased its guidelines, allowing women to use the pill further into pregnancy and with fewer visits to their doctor.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.